Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fluorine F 18 d-FMAU is a radiolabeled nucleoside analog and a thymidine derivative used as a PET imaging tracer. Specifically, it is the D-enantiomer of 2'-fluoro-5-methyl-1-beta-D-arabinofuranosyluracil labeled with the positron-emitting isotope fluorine-18. It acts as a substrate for thymidine kinase enzymes, particularly thymidine kinase 1 (TK1), which is associated with cellular proliferation, and mitochondrial thymidine kinase 2 (TK2). Once transported into cells, it undergoes phosphorylation by these kinases, leading to intracellular metabolic trapping and incorporation into DNA. This mechanism allows for the visualization of high-proliferation tissues and mitochondrial activity using Positron Emission Tomography/Computed Tomography (PET/CT), making it a valuable tool for diagnosing, staging, and monitoring the treatment response of various malignancies, including prostate and other advanced cancers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fluorine F 18 d-FMAU.